Recent News
- Affinium Pharmaceuticals, Ltd., Announces First Patient Dosed with Oral AFN-1252 in a Phase 2 Clinical Trial
Austin, Texas and Toronto, Ontario, February 1, 2012 - Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI").
- View Full Article
- Profound Medical Inc. Appoints New CEO
Profound Medical Inc. (PMI) a company pioneering a unique, minimally invasive approach for the treatment of prostate cancer announced today that Mr. Steven Plymale will assume the role of Chief Executive Officer of the company.
- Download the article
- Functional Neuromodulation Inc. Closes Financing Agreements to Fund Phase II Testing for Potential Alzheimer's Treatment
October 17, 2011, Toronto, Ontario: Functional Neuromodulation Inc, a company advancing deep brain stimulation (DBS) therapies for Alzheimer's Disease, today announced the closing of $10.4 million in commitments from Genesys Capital and Medtronic, Inc. in its latest round of financing.
- View Full Article
- Affinium Pharmaceuticals Announces the Closing of $15 Million Financing
Toronto, Ontario and Austin, Texas, August 29, 2011 - Affinium Pharmaceuticals announced today the closing of its $15 million financing.
- Download the article
- gIcare Pharma Inc Closes $7 Million Series A Financing
MONTREAL (Quebec), Canada - gIcare Pharma Inc announced the closing of a seven million dollar (7M$US) Series A financing, today.
- Download the article